Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Gut barrier and microbiota changes with glycine and branched-chain amino acid supplementation in chronic haemodialysis patients.

Tytuł:
Gut barrier and microbiota changes with glycine and branched-chain amino acid supplementation in chronic haemodialysis patients.
Autorzy:
Genton L; Unit of Nutrition, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Pruijm M; Service of Nephrology, University Hospitals of Lausanne and University of Lausanne, Lausanne, Switzerland.
Teta D; Service of Nephrology, Cantonal Hospital of Sion, Sion, Switzerland.
Bassi I; Service of Nephrology, Cantonal Hospital of Sion, Sion, Switzerland.
Cani PD; Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Université catholique de Louvain, Brussels, Belgium.
Gaïa N; Genomic Research Lab and Service of Infectious Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Herrmann FR; Department of Rehabilitation and Geriatrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Marangon N; Service of Nephrology, Geneva University Hospitals and Clinique of Champel, Geneva, Switzerland.
Mareschal J; Unit of Nutrition, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Muccioli GG; Louvain Drug Research Institute, Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Université catholique de Louvain, Brussels, Belgium.
Stoermann C; Service of Nephrology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Suriano F; Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Université catholique de Louvain, Brussels, Belgium.
Wurzner-Ghajarzadeh A; Service of Nephrology, University Hospitals of Lausanne and University of Lausanne, Lausanne, Switzerland.
Lazarevic V; Genomic Research Lab and Service of Infectious Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Schrenzel J; Genomic Research Lab and Service of Infectious Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Źródło:
Journal of cachexia, sarcopenia and muscle [J Cachexia Sarcopenia Muscle] 2021 Dec; Vol. 12 (6), pp. 1527-1539. Date of Electronic Publication: 2021 Sep 18.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 2015- : Berlin : John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders
Original Publication: Heidelburg : Springer-Verlag
MeSH Terms:
Glycine*
Microbiota*
Amino Acids, Branched-Chain ; Cross-Over Studies ; Dietary Supplements ; Humans ; RNA, Ribosomal, 16S/genetics ; Renal Dialysis
References:
Amino Acids. 2012 May;42(5):1597-608. (PMID: 21344175)
BMC Pulm Med. 2017 Dec 15;17(1):206. (PMID: 29246256)
Kidney Int. 2006 Aug;70(3):417-22. (PMID: 16775598)
J Ren Nutr. 2014 Sep;24(5):330-5. (PMID: 25066654)
Science. 2016 Feb 19;351(6275):. (PMID: 26912898)
Bioinformatics. 2010 Oct 1;26(19):2460-1. (PMID: 20709691)
Microb Ecol Health Dis. 2015 May 29;26:27663. (PMID: 26028277)
World J Gastrointest Pharmacol Ther. 2017 Feb 6;8(1):39-46. (PMID: 28217373)
Am J Kidney Dis. 2016 Feb;67(2):283-92. (PMID: 26612280)
Gut. 2009 Aug;58(8):1091-103. (PMID: 19240062)
mBio. 2019 Jun 18;10(3):. (PMID: 31213556)
Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G213-21. (PMID: 16123201)
BMJ. 2019 Jul 31;366:l4378. (PMID: 31366597)
J Physiol. 2010 Mar 15;588(Pt 6):995-1009. (PMID: 20123783)
Int J Syst Evol Microbiol. 2017 May;67(5):1613-1617. (PMID: 28005526)
J Ren Nutr. 2018 Nov;28(6):380-392. (PMID: 30348259)
Shock. 2009 Oct;32(4):374-8. (PMID: 19295480)
Clin Nutr. 2015 Jun;34(3):341-9. (PMID: 25459400)
Gut. 2005 Sep;54(9):1224-31. (PMID: 16099790)
Gastroenterology. 2003 Jun;124(7):1792-801. (PMID: 12806613)
Science. 2015 Oct 30;350(6260):558-63. (PMID: 26516283)
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):1081-1083. (PMID: 29098794)
Am J Clin Nutr. 1998 Jul;68(1):72-81. (PMID: 9665099)
J Endocrinol Invest. 2008 Aug;31(8):694-9. (PMID: 18852529)
J Transl Med. 2019 Jan 3;17(1):5. (PMID: 30602367)
Int J Biochem Cell Biol. 2013 Oct;45(10):2186-90. (PMID: 23831839)
Am J Clin Nutr. 2020 May 1;111(5):1087-1099. (PMID: 31942927)
Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii6-iii11. (PMID: 30281131)
Nephrol Dial Transplant. 2001 Sep;16(9):1856-62. (PMID: 11522870)
Sci Transl Med. 2019 Jul 24;11(502):. (PMID: 31341063)
Kidney Int. 2013 Feb;83(2):308-15. (PMID: 22992469)
Anal Bioanal Chem. 2016 Jan;408(3):733-45. (PMID: 26563111)
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1527-1539. (PMID: 34535959)
Nutr Res. 2016 Jul;36(7):658-62. (PMID: 27333956)
Genes Nutr. 2017 Oct 4;12:27. (PMID: 29043007)
BMC Microbiol. 2016 Apr 23;16:73. (PMID: 27107811)
Amino Acids. 2016 Dec;48(12):2731-2745. (PMID: 27539648)
Swiss Med Wkly. 2004 Mar 6;134(9-10):117-25. (PMID: 15106021)
ISME J. 2016 Jun;10(6):1456-70. (PMID: 26613342)
J Natl Cancer Inst. 1996 Apr 17;88(8):550-2. (PMID: 8606384)
Grant Information:
320030_163144 Switzerland SNSF_ Swiss National Science Foundation
Contributed Indexing:
Keywords: Appetite; Branched-chain amino acid malnutrition; Endocannabinoids; Glycine; Gut microbiota
Molecular Sequence:
ClinicalTrials.gov NCT02962089
Substance Nomenclature:
0 (Amino Acids, Branched-Chain)
0 (RNA, Ribosomal, 16S)
TE7660XO1C (Glycine)
Entry Date(s):
Date Created: 20210918 Date Completed: 20220128 Latest Revision: 20220128
Update Code:
20240105
PubMed Central ID:
PMC8718035
DOI:
10.1002/jcsm.12781
PMID:
34535959
Czasopismo naukowe
Background: We have previously shown that glycine increases fat-free mass in chronic haemodialysis patients with features of malnutrition as compared with branched-chain amino acids (BCAAs). This multicentre randomized double-blind crossover study evaluates the impact of these amino acids on the gut barrier and microbiota.
Methods: Haemodialysis patients were included if they had plasma albumin <38 g/L or weight loss >5% of dry body weight, and daily dietary intakes <30 kcal/kg and <1 g protein/kg. They consumed glycine or BCAA (7 g twice daily) for 4 months and underwent a 1 month washout period, before crossover of supplementations. Faecal microbiota (16S rRNA gene sequencing) and immunoglobulin A (IgA), serum levels of cytokines, surrogate markers of intestinal permeability, appetite mediators, and endocannabinoids were obtained at the start and end of each supplementation. Supplementations were compared by multiple mixed linear regression models, adjusted for age, sex, month of supplementation (0 and 4 in each period), and period (Period 1: first 4 months; Period 2: last 4 months). Microbiota comparisons were performed using principal coordinate analysis and permutational multivariate analysis of variance, Shannon diversity index estimate and analysis of composition of microbiomes analysis, and Wilcoxon tests.
Results: We analysed 27 patients compliant to the supplementations. Multiple mixed linear regression models were significant only for interleukin-6 (P = 0.002), glucagon-like peptide 1 (P = 0.028), cholecystokinin (P = 0.021), and peptide YY (P = 0.002), but not for the other outcomes. The significant models did not show any impact of the type of supplementation (P < 0.05 in all models). Principal coordinate analysis and permutational multivariate analysis of variance (P = 0.0001) showed strong microbiota clustering by subject, but no effect of the amino acids. Bacterial alpha diversity and zero-radius operational taxonomic unit richness remained stable, whatever the supplementation. Lacticaseibacillus paracasei (0.030; Q1-Q3 0.008-0.078 vs. 0.004; Q1-Q3 0.001-0.070) and Bifidobacterium dentium (0.0247; Q1-Q3 0.002-0.191 vs. 0.003; Q1-Q3 0.001-0.086) significantly decreased with the BCAA supplementation.
Conclusions: The BCAA and glycine supplementations had no impact on the serum levels of cytokines, appetite mediators, intestinal permeability, endocannabinoids, or faecal IgA. Overall faecal microbiota composition and microbial diversity did not change with the glycine or BCAA supplementation but decreased the abundance of L. paracasei and B. dentium.
(© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies